3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
8
Sarcoma
2
Neoplasms
2
Neoplasm Metastasis
2
Multi-centric Castleman's Disease
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma, Ewing
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Cancer Recurrent
1
Macular dystrophy, corneal type 1
1
Lymphoproliferative Disorders
1
Lymphadenopathy
1
Liposarcoma
1
Leiomyosarcoma
1
Hodgkin Disease
1
Histiocytoma, Malignant Fibrous
1
HIV Infections
1
Gliosarcoma
1
Glioblastoma
1
Fallopian Tube Mucinous Adenocarcinoma
1
Endometrial Neoplasms
1
Interventions
pembrolizumab
30
Paclitaxel
12
Carboplatin
10
Cisplatin
8
lenvatinib
7
Pemetrexed
5
belzutifan
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Capecitabine
4
patritumab deruxtecan
3
olaparib
3
Leucovorin
3
Albumin-Bound Paclitaxel
3
Acetaminophen
3
Levoleucovorin
2
Irinotecan
2
Histamine H2 Antagonists
2
Histamine Antagonists
2
Etoposide
2
Docetaxel
2
Dexamethasone
2
Cetuximab
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
liposomal doxorubicin
×
30 days
×
Clear all
NCT06312176
2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,200 enrolled